pHGGs, including glioblastoma and DIPGs, and pediatric and juvenile HGGs are unique in that H3-K27M mutation occurs in more than half of cases, and the activity of EZH2 (histone-lysine N-methyltransferase Enhancer of zeste homolog 2) is suppressed by the H3-K27M mutation (68). This evidence concerns the gene EZH2 and glioblastoma.